Skip to content

Trial Summary

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression.

Acronym:

FORTITUDE-102

ACTRN/NCT /ethics:

NCT05111626

Scientific title:

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Sponsor / Cooperative group:

Amgen

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase I; Phase III
Age Range18 years to 100 years
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2022-03-14
Anticipated End Date2026-05-11

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Emailstella.papacharissiou@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Timothy Price
Recruitment StatusNot Yet Recruiting